ArticleJournal of clinical and translational hepatology2021
Chronic Hepatitis B Infection with Low Level Viremia Correlates with the Progression of the Liver Disease.
Article in Journal of clinical and translational hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Prevalence of low-level viremia in the treatment of chronic hepatitis B in China: a systematic review and meta-analysis.BMJ open · 2025Pooled it
- [Clinical study on the efficacy of Wuling capsules combined with nucleos(t)ide analogues in the treatment of low-level viremia patients with chronic hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Trial
- Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Virus Infection in the High-Replicative Low-Inflammatory Phase: A 48-Week Randomized Controlled Trial.Journal of medical virology · 2026Trial
- Maintaining versus switching antiviral therapy in chronic hepatitis B patients with low-level viremia.Journal of virus eradication · 2026Article
- RRM2B is associated with low-level viremia during entecavir therapy in pediatric chronic hepatitis B and promotes profibrotic signaling in vitro.Virology journal · 2026Article
- KASL clinical practice guidelines for management of chronic hepatitis B Endorsed by the East Asia Liver Alliance (EALA).Clinical and molecular hepatology · 2026Article
- Serological and Demographic Correlates of HBV DNA Detection Below the Limit of Quantification in Treated Chronic Hepatitis B and HBsAg-Negative Patients.Biomedicines · 2026Article
- Effectiveness and safety of tenofovir amibufenamide in the treatment of chronic hepatitis B patients with low-level viremia: a retrospective real-world study.BMC gastroenterology · 2026Article
- Occult hepatitis B virus infection among hepatitis B surface antigen negative vaccinated healthcare workers in East Gojjam zone hospitals.Scientific reports · 2026Article
- Predictors of low-level viremia in chronic hepatitis B and the efficacy of pegylated interferon-alpha: a real-world study.Virology journal · 2025Article
- Reevaluating antiviral thresholds in HBV DNA-negative inactive HBsAg carriers: a multicenter histopathological analysis.Virology journal · 2025Article
- Serum hepatitis B virus RNA in low-level viremia of chronic hepatitis B: clinical features and association with virological response.Virology journal · 2025Article
- Low-Level Viremia Impairs Efficacy of Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0.Clinical and molecular hepatology · 2025Review
- Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B: Detailed Analysis of Treatment-Naive and Experienced Patients.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2025Article
- Existing problems and new advice on stage criteria of natural history for chronic hepatitis B.BMC infectious diseases · 2025Review
- Relationship Between Nucleos(t)ide analogue antiviral response time and prognosis in Chronic Hepatitis B: conclusions depend on baseline viral load and HBeAg status.Frontiers in pharmacology · 2025Article
- Adding pegylated interferon-α to nucleos(t)ide analogs improves HBsAg clearance in chronic hepatitis B with low-level viremia.Frontiers in medicine · 2025Article
- Unveiling low level viremia in chronic hepatitis B: challenges and new horizons.Frontiers in cellular and infection microbiology · 2025Review
- Pegylated Interferon-α-Induced Functional Cure for Special Populations with Chronic Hepatitis B Virus Infection: Current Trends, Challenges and Prospection.Drug design, development and therapy · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsCurrently, insufficient clinical data are available to address whether low-level viremia (LLV) observed during antiviral treatment will adversely affect the clinical outcome or whether treatment strategies should be altered if LLV occurs. This study compared the clinical outcomes of patients with a maintained virological response (MVR) and patients who experienced LLV and their treatment strategies.
methodsA retrospective cohort of 674 patients with chronic hepatitis B virus (HBV) infection who received antiviral treatment for more than 12 months was analyzed for the development of end-stage liver disease and treatment strategies during the follow-up period. End-stage liver disease included decompensated liver cirrhosis and hepatocellular carcinoma (HCC).
resultsDuring a median 42-month follow-up, end-stage liver disease developed more frequently in patients who experienced LLV than in those who experienced MVR (7.73% and 15.85% vs. 0.77% and 5.52% at 5 and 10 years, respectively;
conclusionsLLV is an independent risk factor for end-stage liver disease and HCC, and treatment adjustments can be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.